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Cancer B-cellAnti-apoptotic Bcl-2 contributes to cancer formation and progression by promoting the survival of altered cells.
Hence, it is a prime target for novel speciﬁc anti-cancer therapeutics. In addition to its canonical anti-apoptotic
role, Bcl-2 has an inhibitory effect on cell-cycle progression. Bcl-2 acts at two different intracellular compartments,
the mitochondria and the endoplasmic reticulum (ER). At the mitochondria, Bcl-2 via its hydrophobic cleft
scaffolds the Bcl-2-homology (BH) domain 3 (BH3) of pro-apoptotic Bcl-2-family members. Small molecules
(like BH3 mimetics) can disrupt this interaction, resulting in apoptotic cell death in cancer cells. At the ER,
Bcl-2 modulates Ca2+ signaling, thereby promoting proliferation while increasing resistance to apoptosis.
Bcl-2 at the ER acts via its N-terminal BH4 domain, which directly binds and inhibits the inositol 1,4,5-trisphos-
phate receptor (IP3R), the main intracellular Ca2+-release channel. Tools targeting the BH4 domain of Bcl-2
reverse Bcl-2's inhibitory action on IP3Rs and trigger pro-apoptotic Ca2+ signaling in cancer B-cells, including
chronic lymphocytic leukemia (CLL) cells and diffuse large B-cell lymphoma (DLBCL) cells. The sensitivity of
DLBCL cells to BH4-domain targeting tools strongly correlated with the expression levels of the IP3R2 channel,
the IP3R isoform with the highest afﬁnity for IP3. Interestingly, bio-informatic analysis of a database of primary
CLL patient cells also revealed a transcriptional upregulation of IP3R2. Finally, this review proposes a model, in
which cancer cell survival depends on Bcl-2 at the mitochondria and/or the ER. This dependence likely will
have an impact on their responses to BH3-mimetic drugs and BH4-domain targeting tools. This article is part
of a Special Issue entitled: Calcium signaling in health and disease. Guest Editors: Geert Bultynck, Jacques Haiech,
Claus W. Heizmann, Joachim Krebs, and Marc Moreau.
© 2014 Elsevier B.V. All rights reserved.nhibitor-1; BH, Bcl-2-homology;
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l),1. Introduction
Bcl-2, the foundingmember of the Bcl-2 family, derives its name from
B-cell lymphoma 2. It was initially described in 14;18 chromosome trans-
locations, which are a characteristic of follicular lymphoma, the most
common lymphoma in humans [1,2]. The Bcl-2-protein family regulates
cell death and proliferation [3,4], two processes dysregulated during on-
cogenic transformation. Thus, it is not surprising to ﬁnd an upregulation
of Bcl-2 expression in many cancers, including chronic lymphocytic leu-
kemia (CLL) and diffuse large B-cell lymphoma (DLBCL) [5,6].
Intracellular Ca2+ signals originating from the endoplasmic reticu-
lum (ER), the main intracellular Ca2+-storage organelle, also control
cell death and proliferation [7]. In particular, the close proximity of the
ER and the mitochondria allows a swift and prominent accumulation
of Ca2+ into the mitochondria, not only in response to physiological
agonists but also in response to apoptotic stimuli that promote Ca2+
release from the ER [8–10]. Moreover, intracellular Ca2+ elevation
induces calcineurin (CN)-dependent dephosphorylation and activation
of Bad, a pro-apoptotic Bcl-2 protein, leading to Bcl-2 antagonism and
mitochondrial outer membrane permeabilization (MOMP) [11]. In
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14-3-3 scaffold proteins and thus cannot interact with Bcl-2 or Bcl-Xl
[12]. The inositol 1,4,5-trisphosphate receptor (IP3R) is the main intra-
cellular Ca2+-release channel located in the ER. Importantly, a
subfraction of the IP3Rs is located in a microdomain of the ER, namely
the mitochondria-associated ER membranes (MAMs) [10,13–15]. The
magnitude and the duration of Ca2+ signals derived from the IP3Rs are
decisive for the cell fate, for which small Ca2+ oscillations promote mi-
tochondrial bioenergetics and cellular proliferation, while large Ca2+
transients causeMOMPand subsequent apoptosis [16,17]. It is therefore
not surprising that Bcl-2 proteins also act at the level of the ER as critical
regulators of the IP3R channels, thereby assuring Ca2+-dependent cell
proliferation while protecting them from apoptosis. In this review, the
key determinants of Bcl-2's action at the mitochondria and at the ER
are discussed, thereby illustrating two different strategies that cancer
cells can use to promote survival.
2. The canonical anti-apoptotic role of Bcl-2 at the mitochondria
The Bcl-2 family of proteins is essentially studied for its role in
apoptosis [18–21]. Apoptosis is a programmed cell death morphologi-
cally characterized by membrane blebbing, cell shrinkage, chromatin
condensation and chromosomal DNA fragmentation [22]. Under physi-
ological conditions, apoptosis is a non-immunogenic cell death, because
the produced apoptotic bodies are removed by the phagocytic cells
before the contents of the dying cell can induce an inﬂammatory
reaction [23]. There are two distinct signaling pathways that lead to
apoptosis: (i) the extrinsic or extracellular pathway induced, for
example, by an infection that activates a receptor-mediated process,
like the tumor necrosis factor receptor (TNFR) [24] or the Fas receptor
(FasR) [25] and (ii) the intrinsic or mitochondria-mediated pathway
[26–28]. The intrinsic apoptosis signaling pathway is operated by
the Bcl-2-family members, which are generally divided into three
categories (anti-apoptotic proteins, pro-apoptotic executioners and
pro-apoptotic BH3-only proteins) based on their intracellular function
and sequence homology [29]. The anti-apoptotic Bcl-2 proteins like
Bcl-2, Bcl-w, Mcl-1, Bﬂ-1 and Bcl-Xl which contain all four Bcl-2-
homology (BH) domains 1–4 (BH1–4), can interact with both pro-
apoptotic categories, the multi-domain executioner proteins Bax and
Bak and the BH3-only proteins. The latter consist of two groups:
the activator BH3-only proteins, which can directly activate the
executioners Bax and Bak, like Puma, Bim, and Bid and the sensitizer
BH3-only proteins, like Bad, Bik, Noxa and Bmf which de-repress
Bcl-2's anti-apoptotic function but cannot directly activate Bax and
Bak [28] (Table 1). Mechanistically, anti-apoptotic family members
prevent death by binding and sequestering the BH3 domains of
activator BH3-only proteins and preventing their interaction with Bax/
Bak [30,31]. The sensitizers BH3-only proteins induce Bax/Bak oligo-
merization indirectly by binding anti-apoptotic proteins and thereby
displacing activator BH3-only proteins [31]. Very recently, a selective
role for Bid and Bim as activator BH3-only proteins has been discovered:
Bid preferentially switches on Bak, while Bim preferentially switches on
Bax [32] (Fig. 1).
After their oligomerization induced by the BH3-only proteins, Bax
and Bak directly cause MOMP, a critical step during apoptosis [26,27,Table 1
The Bcl-2 family members are divided into three categories based on their intracellular
function and sequence homology.
Anti-apoptotic Pro-apoptotic
All four BH domains (BH1–4) Multi-domain
(BH1–3)
BH3-only proteins
Sequestrate their pro-apoptotic
counterparts
Executioners Activators Sensitizers
Bcl-2, Bcl-XI, Bcl-w, Bﬂ-1
and Mcl-1
Bax and Bak Bim and Bid Bad, Bik, Noxa
and Bmf33]. Cytochrome c is released after MOMP leading to the activation of
caspases and the subsequent progression toward dismantling of the
cell [27]. Practically, post-MOMP, mitochondria are impaired in their
ability to generate adenosine triphosphate (ATP) and cannot maintain
cellular homeostasis [27,34,35]. Therefore, MOMP is considered as the
point-of-no-return in mitochondrial apoptosis [21].
The balance between pro-survival and pro-death Bcl-2 proteins is a
major factor in determining whether or not cells undergo apoptosis in
response to cell stress. Anti-apoptotic Bcl-2 members can via their
hydrophobic cleft composed by their BH1, 2 and 3 domains, bind and
sequester the pro-apoptotic Bcl-2-family members (Fig. 1). Via this
hydrophobic cleft, the anti-apoptotic Bcl-2 proteins can also interact
with other apoptosis regulators that are not members of the Bcl-2-
protein family, like p53 [28]. Beyond these interactions, Bcl-2 can also
interact with several non-Bcl-2-family proteins via its N-terminal BH4
domain. It can e.g. target the serine/threonine protein kinase Raf-1 to
mitochondrial membranes, allowing it to phosphorylate Bad [36].
Moreover, Bcl-2 can sequester active CN and subsequently block the
nuclear factor of activated T-cells (NFAT)-signaling pathway [37].
3. ER-to-mitochondria Ca2+ transfer determines cell fate
3.1. Ca2+ is a key factor in mitochondria-based cell fate
Mitochondrial homeostasis is essential for the regulation of bio-
energetics, cell proliferation, cell death and autophagy, a survival
mechanism that involves cell degradation of unnecessary cellular com-
ponents in order to produce energy [7,9,17,38–41]. In fact, Ca2+ is a key
regulator of mitochondrial homeostasis and consequently has a pivotal
role in determining cell fate [41].Whilemoderate Ca2+ levels are essen-
tial for normal mitochondrial activities, mitochondrial overload of Ca2+
is detrimental for the morphology of this energetic organelle. High
mitochondrial Ca2+ levels cause mitochondrial depolarization, thereby
opening the mitochondrial permeability transition pore (mPTP),
whose molecular nature has recently been identiﬁed as the c subunit
of the F0F1-ATPase [42-44]. mPTP opening leads tomitochondrial swell-
ing and MOMP, the point-of-no-return for apoptosis induction by trig-
gering the release of cytochrome c [44]. Recently, mitochondrial Ca2+
overload has also been implicated in mitophagy, the selective degrada-
tion of damaged mitochondria through autophagy (as reviewed in
[14]). In contrast, too lowmitochondrial Ca2+ levels reduceATPproduc-
tion, thereby leading to the activation of AMP-activated kinase and the
induction of autophagy [45].
3.2. The IP3R is an ER Ca
2+ channel playing a central role in cell-fate
decision
TheCa2+ transfer from the ER to themitochondria involves the IP3Rs
and the voltage-dependent anion channel (VDAC) linked through the
75-kDa glucose-regulated protein (GRP75). This molecular bridge, as
well as the presence of other ER–mitochondria tethers like the
mitochondria-shaping proteins mitofusin-1 and -2, helps to establish
ER/mitochondria contacts at the MAMs [9,10,46,47]. The ER-to-
mitochondria Ca2+ transfer depends on the ﬁlling state of the ER Ca2+
stores aswell as on the Ca2+-ﬂux properties of the IP3R [48]. In basal con-
ditions, constitutive low-level IP3R-mediated Ca2+ release is essential to
fuel mitochondria with Ca2+ necessary for the activity of mitochondrial
enzymes like pyruvate-, α-ketoglutarate- and isocitrate-dehydrogenases
[45,49,50]. Basal Ca2+ oscillations are responsible for the production
of ATP and nicotinamide adenine dinucleotide phosphate (NADPH).
Ca2+ also indirectly fuels bioenergetics by stimulating substrate trans-
porters such as the ARALAR/AGC1-malate aspartate shuttle [51,52].
Previous data have shown that sensitizing the IP3R to basal IP3 levels,
as via interaction with Bcl-Xl, promotes bioenergetics and cell survival
[53,54]. Furthermore, in normal cells, the inhibition of the IP3R-
dependent Ca2+ ﬂuxes induces basal autophagy as a pro-survival
Fig. 1. Dual role of anti-apoptotic Bcl-2 at both the mitochondria and the ER. At the mitochondria, Bcl-2 binds Bax/Bak via its hydrophobic groove composed of the BH1, 2 and 3 (yellow
boxes), preventing their oligomerization and inhibiting Bax/Bak-pore formation. This can be counteracted by the action of sensitizer BH3-only domains (Bad) or mimicking molecules
(BH3 mimetics). Bid preferentially activates Bak and Bim preferentially activates Bax, leading to Bax/Bak-dependent pore formation followed by MOMP, the point-of-no-return in
apoptosis. At the ER, Bcl-2 interacts with the IP3R via its N-terminal BH4 domain (green box), thereby inhibiting its Ca2+-ﬂux properties. The IP3R mimetics (like TAT-IDPS) can relieve
the inhibition of IP3Rs by Bcl-2, leading to increased Ca2+ signaling in the presence of constitutive IP3 production in cancer cells. The released Ca2+ could be gated into the mitochondria
via a protein complex including the VDAC channel, leading tomitochondrial Ca2+ overload, indirectly (dashed line) causing apoptosis. In anti-cancer therapy Bcl-2 can be targeted at both
sites, and both strategies are expected to be complementary.
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tects cells from cell death [56–61]. Some of these studies were based
on IP3R1-deﬁcient B- and T-lymphocytes that are resistant to apoptosis
induced by dexamethasone, T-/B-cell-receptor stimulation, ionizing
radiation, Fas, and staurosporine [56,57]. Moreover, speciﬁc inhibition
of Ca2+ release from the IP3R strongly blocks lymphocyte apoptosis
[59]. Furthermore, in aging oocytes, the Ca2+ leak from the IP3R1
channel domain after truncation by caspase 3 acts as a feed-forward
mechanism to divert the cell into apoptosis [60]. The anti-apoptotic
phosphoinositide-dependent serine–threonine protein kinase/protein
kinase B (Akt/PKB) has been shown to phosphorylate IP3R3 and IP3R1,
thereby reducing ER Ca2+ release and protecting cells from apoptosis
[61,62]. Recently, it has been shown that the tumor suppressor phos-
phatase and tensin homolog (PTEN) can interact with the IP3R3 at
the ER, and that this correlates with a decrease in Akt/PKB-mediated
phosphorylation of the receptor and a subsequent reduction of Ca2+
release via the IP3R3 [63].Moreover, severalmembers of the transmem-
brane Bax-inhibitor motif (TMBIM) family are located at the ER and
impact survival and apoptosis by directly targeting IP3Rs [64]. For
instance, BI-1 directly binds and stimulates IP3R channels [65]. Interest-
ingly, the stimulatory effect of BI-1 on autophagic ﬂux has been linked
to its ability to promote Ca2+ signaling and thus to lower steady-state
ER Ca2+ levels [55]. However, BI-1 has also been reported to suppress
autophagy by directly targeting and inhibiting the ER-stress sensor,
inositol-requiring enzyme 1 α (IRE1α) [66,67]. Cells lacking BI-1
display IRE1α-mediated c-Jun N-terminal kinase 1 (JNK1) activation
[67], which disrupts the autophagy-inhibiting Bcl-2/Beclin 1 complex
and thus activates autophagy [68]. Another common regulator of
IRE1α and IP3Rs is glutamate receptor ionotropic N-methyl D-
aspartate-associatedprotein (GRINA, or TMBIM3),which is upregulated
in a protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK)/
activating transcription factor 4 (ATF4)-dependent manner during ER
stress andwhich suppresses IP3R-mediated Ca2+ release as an adaptive
protective response [69]. However, excessive ER stress has been associ-
atedwith a prolonged anddetrimental attenuation of the IP3R1 function
by disrupting the complex between IP3R1 and 78 kDa glucose-regulated
protein (GRP78) that is essential for IP3R1-subunit assembly into func-
tional channels [70]. These mechanisms underpin the complex role ofintracellular Ca2+ signaling mediated by IP3Rs in cell survival and cell
death in normal and stress conditions [71].
IP3-induced Ca2+ release (IICR) can also control cell proliferation
independently of its mitochondrial function. Several transcription
factors regulating growth factor expression are known to be regulated
by IICR [72,73]. One typical example is NFAT, that is involved in the tran-
scriptional regulation by cell surface receptors, cytokines (e.g. interleukin
(IL)-2), as well as other transcription factors in lymphocytes. NFAT pro-
teins are dephosphorylated by CN and subsequently translocated from
the cytoplasm to the nucleus. CN is activated by the Ca2+ mobilization
initiated by the IP3R, followed by Ca2+ inﬂux via the stromal interaction
molecule 1 STIM1-mediated Ca2+-release-activated Ca2+-channel
protein 1 (Orai1) [74–78] (Fig. 2). Interestingly, it has been shown
that CN activation protected the leukemic cells from apoptosis induced
by interleukin-2 (IL-2) withdrawal in vitro [72] and favored leukemia
progression in vivo [79].
Due to its critical role in intracellular Ca2+ dynamics, the IP3Rs are
tightly regulated by many proteins, as previously reviewed in [7,41,80,
81]. Dysregulation of the IP3R expression, function or interactome can
result either in an escape from cell death as in some types of cancer,
or in exaggerated cell death as in neurodegenerative diseases [80].
Among this vast group of IP3R-interacting proteins, we will focus in
this review on the role of Bcl-2 in the control of IP3Rs during
cancerogenesis.
3.3. IP3R biology in cancer
Many oncoproteins and tumor suppressors act on the cellular Ca2+-
signaling toolkit to control cell death and proliferation [82]. Moreover, it
becomes increasingly clear that dysregulated Ca2+ homeostasis may
contribute to the survival ofmalignant cells [82]. As such, the expression
and function of different Ca2+-permeable channels and Ca2+ pumps
(like IP3Rs, transient receptor potential (TRP) channels, Orai1, sarco/
endoplasmic reticulum Ca2+-ATPase (SERCA), plasma membrane
Ca2+-ATPase (PMCA) and secretory pathway Ca2+-ATPase (SPCA))
have been reported to be altered in a plethora of cancers [83–85]. A
growing number of studies now indicate that the function of IP3Rs as
signaling platforms is inﬂuenced by different oncoproteins, like Akt/
Fig. 2. Interaction between Bcl-2 and the cell cycle. Bcl-2 can directly or indirectly inhibit the proliferation of cells at different check points of the cell cycle (the check points of the cell cycle
are represented by large red arrows). At theG0/G1 transition phase, Bcl-2 controls the expression pattern of p130, p27 and retinoblastomaprotein (pRb) (not shown in theﬁgure) to induce
an arrest in the G1 phase. Phosphorylation of Bcl-2 (Thr69, Ser70 and Ser87) by JNK1 leads to cell-cycle arrest at G2/M. Bcl-2 interacts with and inhibits calcineurin (CN) and IP3Rs. CN is
activated by IP3-induced Ca2+ release from the ER and subsequent Ca2+ entry via STIM1-gated Orai1 channels. This will result in an increase in cytosolic Ca2+ levels and the activation of
Ca2+/calmodulin (CaM)-dependent phosphatase CN, which will dephosphorylate NFAT proteins. This activated NFAT will translocate to the nucleus, where it drives the transcription of
growth factor genes, like IL-2, IL-3 andGM-CSF. As a consequence of the inhibitory effect of Bcl-2 onboth CNand IP3R, NFATnuclear translocation, and IL-2, IL-3 andGM-CSF expression are
impaired. In the absence of these growth factors, the DNA synthesis during the S phase of the cell cycle is affected.
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interacting protein (KRAP), and by tumor suppressors, like promeolytic
leukemia protein (PML) and Beclin 1 (as reviewed in [7]). These interac-
tions and modiﬁcations may alter IP3R-mediated Ca2+ signaling
and provide cell survival despite the ongoing pro-apoptotic signaling
due to oncogenic stress, to which these cells are exposed in cancer
conditions [37]. The pathways by which cancer cells exploit altered
IP3R-mediated Ca2+ signaling to promote cell survival and/or to
increase resistance to apoptosis, reveal important roles for Akt/PKB
[62], PML [86] and Bcl-2 proteins [87] as inhibitory mechanisms that
prevent toxic IP3R-mediated Ca2+ signaling. These IP3R-interacting pro-
teins show a selective targeting of particular IP3R isoforms [10,61,63,8].
Furthermore, there is growing evidence for a speciﬁc role of IP3R
isoforms in tumorigenesis, metastasis and resistance. For instance, a
prominent role for IP3R3 channels has been implicated in different
types of cancer [89–92]. It has been shown that i) inhibition of IP3R3-
mediated Ca2+ release by caffeine blocks migration of glioblastoma
cells in different in vitro assays [89], ii) the elevation of IP3R3 expression
by estradiol is involved in the role of IICR in the growth of the MCF-7
breast cancer cell line [90], iii) the expression level of IP3R3 in colon can-
cer cells is directly related to aggressiveness of the tumor resulting from
increased resistance to apoptosis [91], and iv) themolecular interaction
and functional coupling between IP3R3 and BKCa, a voltage- and Ca2+-
dependent K+ channel, stimulate breast cancer cell proliferation [92].
On the other hand, reduction in IP3R1 mRNA levels was associated
with the acquisition of cisplatin resistance in bladder cancer cells [93].
In fact, the suppression of IP3R1 expression using small interfering
RNA prevented apoptosis and resulted in decreased sensitivity tocisplatin, while overexpression of IP3R1 in resistant cells induced
apoptosis and increased sensitivity to cisplatin [93].
4. Bcl-2 at the ER: protection against excessive IP3R-mediated Ca2+
signaling in B-cell cancers
Different Bcl-2-familymembers have been described to be located at
intracellular membranes other than the mitochondria, including the ER
[94–97]. These Bcl-2-family members can affect different aspects of
ER-related functions [98]. For instance, Bax/Bak proteins directly target
the ER-stress sensor, IRE1α, and are essential for the activation of IRE1α
and downstream unfolded protein response (UPR) signaling [99]. Also,
Bcl-2 proteins have been implicated to recruit pro-apoptotic BH3-only
proteins like Bim to the IRE1α complex as an adaptive mechanism to
sustain UPR signaling during ER stress [100].
Besides thedirect regulation of UPR signaling, Bcl-2 proteins regulate
ER Ca2+ homeostasis and dynamics, which also directly affect protein
folding [39,101–103]. Over the years, strong evidence for the control
of Ca2+ release from the ER by Bcl-2 has been accumulating, but
different, not mutually exclusive mechanisms have been proposed. For
instance, Bcl-2 has been reported to lower the steady-state ER Ca2+-
store content, thereby preventing the occurrence of excessive pro-
apoptotic Ca2+ signals and mitochondrial Ca2+ overload [97,104–107].
It was proposed that increasing the ratio of anti-apoptotic over pro-
apoptotic Bcl-2-family members results in sensitization of IP3R1 to
basal IP3 levels by a protein kinase A (PKA)-dependent phosphorylation
of IP3R1, thereby enhancing the basal Ca2+ leak through sensitized
IP3R1 channels and lowering the ER Ca2+ levels [108]. Other studies
2244 H. Akl et al. / Biochimica et Biophysica Acta 1843 (2014) 2240–2252proposed that Bcl-2 might directly impact the permeability of the ER
membranes by mimicking ion channel functions [109–111]. Yet, the
effect of Bcl-2 on ER Ca2+ store loading has not been conﬁrmed in
other studies [54,112–116]. The reason for these divergent observations
could be related to the different cell models used. An elegant study of
Foskett and co-workers showed that Bcl-Xl overexpression only lowers
the ER Ca2+-store content in DT-40 triple-IP3R knockout cells ectopically
expressing IP3R3, but not in DT40 triple-IP3R knockout cells or DT-40
triple-IP3R knockout cells ectopically expressing IP3R1 or IP3R2 [112].
Thus, the eventual effect of anti-apoptotic Bcl-2 proteins on the
steady-state ER Ca2+ levels may be dependent on the dominant IP3R
isoform expressed in the studied cell types. Alternatively, the effect of
Bcl-2 proteins on the ER Ca2+ content might also be dependent on the
presence of other proteins. For instance, lowering of the ER Ca2+ levels
by Bcl-2/Bcl-Xl overexpression requires the presence of BI-1, since
Bcl-2/Bcl-Xl overexpression fails to lower the ER Ca2+ levels in BI-1-
deﬁcient cells [117]. Thus, the effect of anti-apoptotic Bcl-2 proteins
on the ER Ca2+ levels may also depend on the endogenous BI-1 expres-
sion levels in the studied cell types. BI-1 is a conserved pro-survival
protein that acts as a Ca2+/H+ antiporter [118], a Ca2+ channel [119]
and an IP3R sensitizer [65].
Beyond lowering of the ER Ca2+-store content, Bcl-2 can directly
target and differentially regulate IP3R channels according to the
spatiotemporal nature of the IP3-induced Ca2+ release [115]. In
T-lymphocytes, Bcl-2–IP3R interaction enhances pro-survival Ca2+
oscillations induced by weak T-cell receptor activation while inhibiting
pro-apoptotic transient Ca2+ elevation induced by strong T-cell recep-
tor activity. It has also become clear that the anti-apoptotic Ca2+ effect
of Bcl-2 is due to a direct interaction of its BH4 domain with the IP3R,
independently of its effect on the ER Ca2+-store content [87,113–115,
120,121] (Fig. 1). As such, recombinantly expressed and puriﬁed Bcl-2,
or synthetic BH4-domain peptides, reduces IP3R-single-channel activity
in lipid bilayer experiments and IP3R-mediated Ca2+ ﬂux in perme-
abilized cells [113,114,116,122]. These functional observations were
supported by molecular approaches, showing that Bcl-2 directly binds
IP3Rs. Puriﬁed Bcl-2 or BH4-domain peptides were shown to bind to
the central, modulatory domain of the IP3R. These studies also resulted
in the identiﬁcation of the Bcl-2-binding site on the IP3R between
residues 1389 and 1408. A 20 amino acid peptide covering these resi-
dues (named IP3R-derived peptide (IDP)) was used as a decoy peptide
that binds to Bcl-2 and disrupts the IP3R/Bcl-2-protein complex. A
TAT-fused version of stabilized IDP, generated by eliminating the
predicted protease cleavage site (TAT-IDPS), targets the BH4 domain
of Bcl-2 and disrupts Bcl-2 binding to IP3Rs, and consequently enhanced
agonist-induced Ca2+ rise in a variety of cell types [123,124] (Fig. 1). It
thereby potentiates Ca2+-dependent apoptosis, e.g. in T-lymphocytes
exposed to high [anti-CD3] without being cytotoxic by itself [113,114,
123]. Interestingly, in B-cell malignancies, including CLL and DLBCL,
but not in normal peripheral mononuclear blood cells, TAT-IDPS causes
spontaneous Ca2+ rises and triggers apoptotic cell death in the absence
of any additional apoptotic stimulus [123,124]. Very recently, it
has been reported that Bcl-2 interacts with dopamine- and cAMP-
regulated phosphoprotein of 32 kDa (DARPP-32) [125], an inhibitor of
protein phosphatase 1 (PP1). DARPP-32 is activated by PKA-mediated
phosphorylation at Thr34 and deactivated by CN-mediated dephos-
phorylation at this site [126]. These ﬁndings indicated that Bcl-2 docks
DARPP-32 and CN on the IP3R, creating a negative feedback loop. This
protein complex responds to IP3R-mediated Ca2+ release by inhibiting
IP3R phosphorylation at Ser1755, thereby suppressing excessive Ca2+
release capable of inducing cell death. Interestingly, this Bcl-2–CN–
DARPP-32 feedback mechanism seems to be implicated in the regula-
tion of Ser1755 phosphorylation and apoptosis in primary human CLL
cells. Other anti-apoptotic Bcl-2-family members, including Bcl-Xl and
Mcl-1, also interact with IP3Rs and regulate IP3R-mediated Ca2+ release
[53,54,108,112,127,128]. Interestingly, Bcl-2, Mcl-1 and Bcl-Xl bind
with comparable afﬁnity to the carboxyl termini of all threemammalianIP3R isoforms, enhancing spontaneous IP3R-dependent pro-survival
Ca2+ oscillations and spiking in intact cells in the absence of agonist
stimulation [54]. Moreover, in a recent study, the interaction between
Bcl-Xl and VDAC has been shown to promote mitochondrial matrix
Ca2+ accumulation by increasing Ca2+ transfer across the outer mito-
chondrial membrane, thereby enhancing mitochondrial bioenergetics
and subsequent survival of the cells [129].
5. Bcl-2 interferes with the cell cycle
Although Bcl-2-family proteins are key players in the control of
mitochondria-based apoptosis, they can also control cell proliferation
(Fig. 2). High levels of Bcl-2 were reported to be associated with a
lower proliferative capacity of human lymphoma [130,131], suggesting
a negative control on proliferation. In primarymurine T-lymphocytes, it
was shown that Bcl-2 levels control the duration of the G0 to S phase
transition, with a critical point at the mid G1 phase [4]. In bone
marrow-derived BAF3 cells, Bcl-2 overexpression not only delays the
onset of apoptosis, but also induces a rapid arrest in the G1 phase of
the cell cycle [132]. Moreover, thymocyte turnover is slower in trans-
genic mice overexpressing Bcl-2 than in the control mice. In this
model system and upon in vitro stimulation with mitogens, B- and
T-lymphocytes expressing the Bcl-2 transgene enter the cell cycle
more slowly than control lymphocytes, while Bcl-2-deﬁcient T-cells
show increased cell-cycle progression [133]. It has also been reported
that high Bcl-2 levels increase the doubling time of exponentially
growing cells [134]. Moreover, Bcl-2 controls the expression pattern
of cell-cycle regulators such as p130, p27 and pRb [4]. In general,
the cell cycle control executed by Bcl-2 seems to be associated with its
phosphorylation state. In cycling cells, the anti-apoptotic function of
Bcl-2 is inactivated by JNK1 that becomes activated during the G2/M
phase, thereby phosphorylating Thr69, Ser70 and Ser87. These amino
acids are located within the unstructured loop of Bcl-2 and were
also phosphorylated in response to microtubule-damaging agents
leading to the arrest of the cell cycle at G2/M [135]. Moreover, mutating
these JNK1-phosphorylation sites in Bcl-2 into alanines renders cells
more resistant to apoptotic stimuli. As such, the phosphorylation
of Bcl-2 at the G2/M phase could be a way to eliminate altered or
damaged cells, thereby avoiding their proliferation. Interestingly,
JNK-mediated phosphorylation of Bcl-2 also seems to affect its
ability to modulate ER Ca2+ homeostasis. Wild-type Bcl-2 and the
phospho-dead Bcl-2Thr69Ala/Ser70Ala/Ser87Ala, but not the phosphomimetic
Bcl-2Thr69Glu/Ser70Glu/Ser87Glu mutant, lowers steady-state ER Ca2+ levels
[136]. Interestingly, the effect of Bcl-2 on the cell cycle seems to depend
on its BH4-domain biology, since a mutation of a tyrosine residue
(Tyr28)within the conserved N-terminal BH4 region of Bcl-2 to alanine
(Tyr28Ala), serine (Tyr28Ser) or phenylalanine (Tyr28Phe), markedly
reduces its ability to restrain re-entry of quiescent FDC-P1 myeloid
cells or NIH 3T3 ﬁbroblasts into the cell cycle upon exposure to growth
factors [137]. This mutation does not affect the ability of Bcl-2 to
heterodimerize with pro-apoptotic Bcl-2-family members, indicating
that the role of Bcl-2 in the cell cycle is independent of Bcl-2's effect
on Bax/Bak [137].
In T-cells, delayed cell cycle re-entry induced by Bcl-2 over-
expression is associated with a reduction in IL-2, IL-3 or granulocyte–
macrophage colony-stimulating factor (GM-CSF) expression. As also
stated above, these growth factors are down-regulated due to an
impaired NFAT activation [4]. The BH4 domain of Bcl-2 can sequester
active CN and subsequently inhibit the NFAT-signaling pathway [37].
It could also reduce NFAT nuclear translocation due to its inhibitory
effect on Ca2+ release from IP3Rs [87,113–115,120,121]. As such, by
reducing the Ca2+ release activity of the IP3R, Bcl-2 could also exert an
anti-proliferative role (Fig. 2). However, the addition of exogenous
IL-2 only partially restores cell cycle progression, indicating that the
Ca2+–CN–NFAT pathway is not the only way Bcl-2 inhibits cell cycle
progression [133].
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Bcl-2 is highly expressed at the onset of many cancers [3,4,138]. In
addition to B-cell lymphomas [139], Bcl-2 has been implicated in solid
tumors like prostate cancer [140] and non-small cell lung cancer
[141]. CLL and DLBCL are two examples of Bcl-2-overexpressing blood
cancers [5,6]. One of the mechanisms of Bcl-2 upregulation in cancer
cells is the translocation of the Bcl-2 encoding region of chromosome
18 to chromosome 14, downstream of the antibody heavy chain
enhancer leading to its upregulation [142,143]. In addition, accumulating
evidence indicates that overexpression of Bcl-2 can also occur via an
alteration in microRNAs in CLL and DLBCL [144–149]. For instance, the
microRNAs miR-15a and miR-16-1 that are frequently deleted in CLL,
induce apoptosis by targeting Bcl-2 [144,148]. Moreover, in KPUM-
MS3 and KPUM-UH1 cell lines derived from DLBCL patients, the over-
expression of Bcl-2 correlates with the reduced expression of miR-143
and miR-145 [145].
Sustained proliferative signaling and resistance to cell death are two
hallmarks of cancer development [150]. The common view is that
cancer cells rely on high levels of Bcl-2 to counteract the ongoing upreg-
ulation of pro-apoptotic BH3-only proteins in response to oncogenic
stress [32,151–153]. Bcl-2 neutralizes the activator BH3-only proteins,
Bid and Bim, and the sensitizer BH3-only proteins, Bad, Puma, Bmf
and to a lesser extent Bik [152] (Table 1 and Fig. 1).
In addition to its canonical anti-apoptotic role, Bcl-2 has been shown
to have an inhibitory effect on the cell cycle and to induce cell quies-
cence [137] (Fig. 2). In cancer cells, the cell cycle control function of
Bcl-2-family members can however be dissociated from the apoptosis
control function [4]. Moreover, the inhibitory effect of Bcl-2 during cell
cycle progression may contribute to the indolent nature of lymphomas
highly expressing Bcl-2 [154]. Thus, the reported low tumor prolifera-
tion rate in non-Hodgkin's lymphoma may be a consequence of the
inhibitory effect of Bcl-2 on cell cycle progression [130,131]. Moreover,
patients whose breast cancer tissue shows high levels of Bcl-2 expres-
sion show a better prognosis [155]. In ovarian cancer cells, Bcl-2 delays
cell cycle progression by promoting accumulation of cells in S phase
without affecting the rate of apoptosis [156]. Because of their major
role in the control of apoptosis, the impact of the cell cycle control
function of Bcl-2 family members on tumor development is still not
well deﬁned. Eventually, the dual role of Bcl-2 in the enhancement of
spontaneous IP3R-dependent pro-survival Ca2+ oscillations in the
absence of agonist stimulation [54,115] and in the protection from
excessive IP3-induced pro-apoptotic Ca2+ [87,113–115,120,121] may
also contribute to the oncogenic nature of Bcl-2.
7. Bcl-2-based anti-cancer strategy: primed-to-death cells?
7.1. Primed-to-death at the mitochondria: BH3 mimetics
The concept of cancer cells being “primed-to-death” at the mito-
chondria was originally introduced by Letai and co-workers [157].
Priming-to-death at the mitochondria is related to the status of the
Bcl-2 family members in the cell death program. In primed-to-death
cancer cells, Bcl-2 is not free, but “loaded” with pro-apoptotic BH3-
only proteins like Bim. Hence, cancer cells are addicted to high levels
of Bcl-2 to neutralize their high levels of Bim, upregulated due to the
ongoing oncogenic stress. Thus, antagonism of anti-apoptotic family
members by sensitizer BH3-only domains or BH3-mimickingmolecules
only results in MOMP when the anti-apoptotic proteins are “primed”
with activator BH3 proteins, as is the case in cancer cells but not in
normal cells. Furthermore, the anti-apoptotic family members may be
distinguished from each other based on their afﬁnity for different
BH3-only proteins and their isolated BH3 domain [157–159]. It is
notable that the BH3 domains of activators Bid and Bim are bound to
all anti-apoptotic Bcl-2 proteins, distinguishing them from the sensi-
tizers, which show a more selective pattern of binding. While Bcl-2,Bcl-Xl and Bcl-w proteins interact with the BH3 domain of Bad, Mcl-1
interacts with the two BH3 domains of Noxa, and Bﬂ-1 binds only
PUMA [160]. The same group has developed an elegant technique called
“BH3 proﬁling” to determine the cellular “addiction” to individual
anti-apoptotic proteins [158]. For this, a panel of BH3-domain peptides
derived from the different BH3-only proteins was used to selectively
antagonize the individual anti-apoptotic Bcl-2-family members. Using
puriﬁed mitochondria isolated from cancer cells, the cytochrome c
release in response to BH3-domain peptides is assessed as a tool to iden-
tify blocks in apoptotic pathways in different cancer cells. Mitochondria
of cancer cells lacking BH3-only proteins will undergo MOMP in
response to BH3-domain peptides derived from activator BH3-only
proteins but not of sensitizer BH3-only proteins. Mitochondria of cancer
cells lacking Bax or Bak will be resistant to MOMP in response to
BH3-domain peptides of both activator and sensitizer BH3-only
proteins. Mitochondria of cancer cells requiring anti-apoptotic Bcl-2-
family members to neutralize Bim will undergo MOMP in response to
BH3-domain peptides of both activator and sensitizer BH3-only
proteins. The latter class is indicated as being “primed-to-death”.
Using BH3-domain peptides of different sensitizer BH3-only proteins,
cancer cells' “addiction” to a speciﬁc anti-apoptotic Bcl-2-family
member can be determined. For instance, MOMP induced by Bad-BH3
peptide indicates that the cancer cells require Bcl-2, Bcl-Xl or Bcl-w. In
contrast, MOMP induced by Noxa-BH3 peptide indicates that the cancer
cells require Mcl-1. MOMP induced by PUMA, a promiscuous BH3-
domain peptide targeting all anti-apoptotic Bcl-2-family members,
but not by Bad or Noxa, indicates that the cancer cells require Bﬂ-1.
Different experimental protocols have been established, allowing
determining the “primed-to-death” status of cancer cells based on cyto-
chrome c release from isolated mitochondria. This was done by using
ELISA or based on the mitochondrial potential measured via lipophilic
cation-1 (JC-1) in permeabilized cells [159].
It was shown that BH3 proﬁling and the amount of Bim scaffolded
by anti-apoptotic Bcl-2 proteins can be used as a prediction for the
apoptotic response of cancer cells to chemotherapy [21]. It is proposed
that cancer cells, in which the mitochondria contain high levels of Bcl-
2 and Bim, are typically closer to the “apoptotic threshold”. These cells
are most sensitive to toxic stimuli, including chemotherapeutic drugs
[153,161]. Hence from these recent studies, it seems that the
mitochondrial apoptotic priming (determined by the response to the
promiscuous PUMA peptide) can predict the tumor response to cyto-
toxic chemotherapy, the most common treatment used for human
malignancies [153,161]. The mitochondrial priming state is thereby
not the same in all malignancies [162]. For instance, cancers that are
highly primed are those that respond most favorably to chemotherapy
(blood cancers including CLL), whereas those that are unprimed
respond poorly to chemotherapy (endometrial and renal cell carcino-
mas, serous borderline tumors) [21]. In the latter cases, the therapeutic
window for using chemotherapy, and thereby killing cancer cells while
saving normal cells, would be very limited.
Beyond chemotherapy, it is also clear that targeted induction of
apoptosis and/or inhibition of anti-apoptotic proteins, particularly by
antagonizing anti-apoptotic Bcl-2-family members, have become a
novel therapeutic concept for cancer [163,164]. The experimental
efforts using BH3 peptides have resulted in the development of
BH3-mimetic drugs, like ABT-737 (from Abbott Laboratories) and its
derivatives, including the orally available ABT-263. These BH3mimetics
function by slotting into the hydrophobic groove on the surface of Bcl-2
and Bcl-Xl, thereby blocking their capacity to inhibit apoptosis [165]
(Fig. 1). Indeed, a correlation exists between the sensitivity of mito-
chondria to Bad-BH3 peptides and sensitivity of the cells to ABT-737
[151]. ABT-compounds have activity against multiple types of blood
tumors [166] and some solid tumors [165,167,168]. Since Bcl-Xl activity
is essential for platelet differentiation and survival [169], non-selective
BH3 mimetic Bcl-2/Bcl-Xl antagonists result in thrombocytopenia and
thrombocytopathy [170]. By comparing the effects of ABT-737 and its
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has become clear that these Bcl-2/Bcl-Xl inhibitors induce apoptosis at
similar concentrations in leukemia cells and platelets [167,171]. These
in vitro ﬁndings correlate well with a phase I study, which showed
that thrombocytopenia was the main factor for the observed dose-
limiting toxicity observed in CLL patients treated with ABT-263 [172].
Dysregulation of the intracellular Ca2+ homeostasis in platelets by
ABT-737 has been reported to be implicated in this phenomenon, but
this remains a controversial issue [171,173]. We have recently shown
that unlike HA14-1, a non-speciﬁc Bcl-2 antagonist, which causes ER
Ca2+ uptake inhibition in platelets and various human cell lines [174],
ABT-737-induced thrombocytopenia is not caused by a dysregulation
of intracellular Ca2+ homeostasis or dynamics (e.g. in response to
thrombin) in platelets [175]. Thus, the observed dysregulation of Ca2+
signaling in ABT-737-treated platelets could be a consequence rather
than being the cause of cell death.
A new BH3mimetic with speciﬁc action on Bcl-2, ABT-199, has been
developed and has no adverse effects on platelets but is still efﬁciently
killing cancer cells [166]. It has been shown to be effective in non-
Hodgkin's lymphoma, CLL, t(11; 14) multiple myeloma [176] and
receptor-positive breast cancer [177]. Additionally, the BH3 mimetics
may increase the sensitivity of tumors such as small-cell lung cancer
to conventional chemotherapeutics, by removing blocks on the activa-
tion of apoptosis pathways [178]. In all cases, cancer cells are still able
to develop resistance to any treatment however. Hence, it remains
very relevant to ﬁnd drug combinations, which could induce synergistic
effects, preventing resistance development and overdose-related
adverse effects.
There is crosstalk between the Bcl-2 family members and the path-
ways implicated in cell cycle progression, including mitogen-activated
protein kinase (MAPK)–extracellular-signal-regulated kinases (ERK)
and phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K)–Akt/PKB–
PTEN. Both pathways are known to be classical drivers of G1 to S
phase progression [179,180]. In diverse cell types, activation of ERK1/2
signaling can lead either to the upregulation of pro-survival proteins
of the Bcl-2 family, notably Bcl-2, Bcl-Xl and Mcl-1, or to the decrease
or inactivation of pro-apoptotic proteins such as Bim to achieve cell
survival [181]. Bim expression is subjected to control both at the tran-
scriptional and the post-translational levels [182] that are governed by
various signaling pathways, including the ERK1/2 and PI3K–Akt/PKB
pathways [181]. Interestingly, the knockdown of Bim can rescue HS2
leukemic cells from apoptosis induced by the MAPK–ERK pathway
inhibitor, U0126 [183]. Moreover, the combination of Obatoclax, a
non-speciﬁc Bcl-2 inhibitor to induce apoptosis, with NVP-BEZ235, a
PI3K inhibitor to reduce cell proliferation, is required for a complete
eradication of leukemic growth [183]. Hence, the combination of BH3
mimetics with cell cycle inhibitors likely will be instrumental for the
treatment of leukemias.
Finally, it is important to note that BH3mimetics (or othermolecules
that target the hydrophobic cleft of Bcl-2) might also affect signaling
complexes at the ER. For instance, the molecular determinants respon-
sible for Bcl-2, Bcl-Xl and/or Mcl-1 binding to the C-terminal site of
the IP3Rs are not yet understood, but a contribution of the hydrophobic
cleft should be considered [17]. Bcl-2 inhibitors, HA14-1 and BH3I-2’,
have been associated with IP3R- and ryanodine receptor-dependent
Ca2+ release in pancreatic acinar cells [184]. However, these
compounds seem not to be speciﬁc for Bcl-2 and can induce cell death
independently of Bax/Bak [185]. At least HA14-1 inhibited SERCA Ca2+
ATPase and caused intracellular Ca2+ dysregulation [175]. In any case,
speciﬁc Bcl-2 antagonism using ABT-737 did not trigger Ca2+-
signaling events in primary CLL cells [123]. Besides the potential effects
of BH3mimetics on the IP3R channels, they can also affect IRE1α activa-
tion during prolonged ER stress [100]. BH3-only proteins (like Bim and
Puma) have been implicated in establishing sustained IRE1α signaling
in cells exposed to prolonged ER stress. Interestingly, the formation of
complexes between these BH3-only proteins and Bcl-2 (but not Bcl-Xlor Mcl-1) seems to be required for sustained IRE1α signaling and
promoting an early adaptive response by upregulating UPR genes via
X-box binding protein 1 (XBP-1) splicing (XBP1-s). The kinetic proﬁle
of these adaptive UPR responses clearly precedes pro-apoptotic BH3-
only functions at the mitochondria. BH3 mimetics, like ABT-737, and
Bad prevent this sustained IRE1α signaling by disrupting the Bcl-2/
Bim complexes. Hence, it is clear that BH3-mimetic compounds may
negatively impact the survival of (cancer) cells by abrogating sustained
IRE1α activation needed for engaging an adaptive UPR program.
7.2. Primed-to-death at the ER: BH4-domain-targeting peptides
Given Bcl-2's critical role at the ER where it suppresses toxic Ca2+-
signaling events, we anticipate that cancer cells might be addicted
to Bcl-2 at the ER Ca2+ stores for their survival, likely via the BH4-
domain biology of Bcl-2. Indeed, exposing primary CLL cells or DLBCL
cell lines to TAT-IDPS, a peptide that targets the BH4 domain of Bcl-2,
results in spontaneous pro-apoptotic Ca2+ spikes and mitochondrial
Ca2+ overload, eventually leading to apoptotic cell death [123,124]. In
a set of DLBCL cell lines, we found a heterogeneous response to TAT-
IDPS treatment. Strikingly, TAT-IDPS-induced Ca2+ rise in the cytosol
and TAT-IDPS-induced apoptosis correlate with the expression level of
IP3R2 levels but neither with the total IP3R levels nor with the levels of
IP3R1 or IP3R3 channels. Interestingly, IP3R2 is the IP3R isoform with
the highest sensitivity to its ligand IP3 [186]. Thus, high IP3R2 levels
may render cancer cells vulnerable to basal IP3 concentrations, thereby
leading to mitochondrial Ca2+ overload and MOMP [11], and/or deple-
tion of the ER Ca2+ stores, leading to chronic ER stress and apoptosis
[187,188]. In particular, basal IP3 signaling might be elevated in CLL
and DLBCL cells, since they display chronic B-cell-receptor signaling
[189,190]. As such, the presence of the IP3R2 hypersensitive channels
may be one of the factors that contribute to cancer cells being
“primed-to-death” at the level of the ER through a mechanism that
drives Ca2+-mediated apoptosis. In contrast, TAT-IDPS-resistant DLBCL
cellsmainly express IP3R3, although there is no such striking correlation
as with TAT-IDPS-sensitivity and IP3R2 expression [124]. The IP3
levels in chronically activated B-cells may not be sufﬁcient to trigger
activation of IP3R3, which is the least sensitive IP3R isoform. As a
result, cells expressing IP3R3 may not require Bcl-2 at the ER, given
the low sensitivity of this isoform to basal IP3 signaling. This concept is
supported by co-immunoprecipitation experiments using cell lysates
from TAT-IDPS-sensitive and -resistant DLBCL cell lines [124]. These
experiments showed that the fraction of the total amount of Bcl-2
that co-immunoprecipitates with IP3R2 in TAT-IDPS-sensitive DLBCL
cells is much larger than the fraction of total Bcl-2 that co-
immunoprecipitates with IP3R3 in TAT-IDPS-resistant DLBCL cells. It is
important to note that in surface plasmon resonance-binding experi-
ments in vitro, all IP3R isoforms are capable to interact with the
BH4 domain of Bcl-2 [116]. Additional parameters affect themechanism
of IP3R regulation by Bcl-2, which could differ for the particular isoform.
For instance, recent reports showed that Akt/PKB, often hyper-activated
in DLBCL cells [191], selectively suppresses Ca2+ ﬂux through IP3R3
subtype channels [61,62]. More recently, the tumor suppressor PTEN
was reported to be located in the MAMs and to counteract Akt/PKB
kinase-mediated reduction in Ca2+ release via IP3Rs by exerting a pro-
tein phosphatase activity [63].
The mechanisms that control IP3R2 (over-)expression in these
cancer cells are not fully understood. Also, the advantage of cancer
cells expressing high levels of potentially “toxic” channels such as the
IP3R2 remains to be investigated. It is remarkable that endogenous
IP3R2 levels are rather low in most tissues. However, IP3R2 channels
seem highly expressed in organs with high metabolism, such as organs
with exocrine functions [192]. Yet, one aspect may involve the role of
IP3R channels and speciﬁc IP3R isoform in controlling cancer cell metab-
olism. In acinar cells, IP3R2 expression levels have been linked to the
sensitivity toward metabolic stress, as IP3R2 is the most sensitive
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depletion on intracellular Ca2+ signaling [193]. Since ATP is a positive
regulator of IP3R activity [193,194], a decline in cellular ATP levels,
e.g. during metabolic stress in cancer cells [195], may therefore
compromise IP3R-mediated Ca2+ signaling necessary for mitochondrial
bioenergetics and their survival. As a consequence, these cells might
compensate this weakened IP3R-mediated Ca2+ signaling by increasing
basal IP3 signaling and by upregulating an IP3R isoform that is more
sensitive to IP3.
To further scrutinize the concept that IP3R2 is a factor that contrib-
utes to the “addiction” of cancer cells to Bcl-2 at the ER and being
primed-to-death at the level of the ER, we performed a search of
the GeneSapiens microarray database website (www.genesapiens.org).
We screened for the expression levels of IP3R2 mRNA across 9783
samples from 175 different types of healthy and diseased tissue sam-
ples, including different tumors [196,197] (Fig. 3). Interestingly, this
analysis shows a high IP3R2 mRNA level in samples from CLL patients.
The CLL B-lymphocytic blast cells are also characterized by a chronic
B-cell-receptor signaling [190]. In fact, this correlates with previous
ﬁndings [123], showing that primary cells obtained from peripheral
blood of CLL patients are very sensitive to BH4-domain targeting
peptides that disrupt Bcl-2–IP3R interaction resulting in Ca2+-driven
apoptosis.
7.3. Opposite sensitivity to BH3-mimetic drugs versus BH4-domain targeting
compounds?
Finally and most interestingly, from the comparison between our
analysis in DLBCL [124] and the results obtained recently by Souers
and co-workers [166], we found that SU-DHL-4 cells that are very
sensitive to TAT-IDPS displayed a low sensitivity to the BH3-mimetic
drugs, ABT-263 (Navitoclax; Abbott Laboratories, the orally bioavailable
version of ABT-737) and ABT-199 (high EC50 values of ~23.3 μM and
7.1 μM, respectively, as shown in [166]) (Fig. 4). On the other hand,Fig. 3. Detailed gene expression proﬁle of IP3R2 across the GeneSapiens microarray database (
levels of human genes across 9.783 Affymetrix gene expression array experiments representin
tumor diseases. 70% of the samples are frommalignant tumors, 19% are fromhealthy tissue and
along the x-axis in a predetermined order,ﬁrst thenormal tissues, then cancers and then other d
silico normalization approach previously described in [196]. Each dot represents the relative exp
bars below the gene plot. Sample types having higher-than-average expression or an outlier e
analysis shows an outlier expression proﬁle of IP3R2 mRNA in chronic lymphocytic leukemia
circulating reticulocytes, in theperipheral nervous systemand in thepancreas. ITPR2 is the geneOCI-LY-1 cells that are very resistant to TAT-IDPS display a very high
sensitivity to BH3-mimetic drugs (low EC50 values of ~0.5 μM and
0.02 μM, respectively, as shown in [166]). Hence, it seems that there is
an opposite response to BH4-domain-targeting tools and BH3-mimetic
tools that target the hydrophobic cleft. It is tempting to speculate
that cancer cells addicted to Bcl-2 at the mitochondria to prevent
Bim-dependent Bax activation, will be particularly sensitive to BH3-
mimetic drugs, while cancer cells addicted to Bcl-2 at the ER to prevent
toxic IP3-induced Ca2+ signaling through IP3R2 channels will be partic-
ularly sensitive to BH4-domain targeting tools (like TAT-IDPs). Clearly,
the concept that cancer cells might be addicted to Bcl-2 at two different
compartments, the mitochondria and the ER, thereby dictating their
apoptotic response to BH3 mimetics and BH4-domain-targeting tools,
ought to be further scrutinized.
8. Conclusion
We propose that the anti-apoptotic function of Bcl-2 in cells occurs
at least at two levels, both at the mitochondria where Bcl-2 prevents
Bim-mediated Bax/Bak activation, and at the ER where Bcl-2 prevents
toxic Ca2+ release through IP3Rs. The “addiction” of cancer cells to
high levels of Bcl-2 may depend on the oncogenic mechanisms that
may upregulate either Bim or IP3R2 channels. Interestingly, different
Bcl-2-protein domains seem to be responsible for its action at the mito-
chondria versus the ER. The hydrophobic cleft of anti-apoptotic Bcl-2
scaffolds and neutralizes pro-apoptotic BH3-only proteins and Bax/Bak
at the mitochondria. As such, cancer cells requiring Bcl-2 at the mito-
chondria will be very sensitive to BH3-mimetic drugs. On the other
hand, the N-terminal BH4 domain of anti-apoptotic Bcl-2 binds and
inhibits pro-apoptotic Ca2+ ﬂux through IP3Rs at the ER. As such, cancer
cells requiring Bcl-2 at the ER will be very sensitive to BH4-domain
targeting drugs. The ﬁeld has signiﬁcantly advanced in understanding
the mechanisms that underlie mitochondrial priming, exploiting these
insights with novel therapeutic drugs, and linking them to the clinicalwww.genesapiens.org). A bioinformatics method for the comparison of mRNA expression
g 43 distinct healthy tissue types, 68 distinct malignant tissue types and 64 distinct non-
11% are fromother diseases. In this GeneSapiens plot, all the 9.783 samples are represented
iseases. The y-axis reﬂects the relative level of IP3R2 gene expression after the three-step in
ression of IP3R2 in one sample. Anatomical origins of each sample aremarkedwith colored
xpression proﬁle are additionally colored in the ﬁgure (legend at the top left corner). This
(CLL) and adrenal gland cancer. The levels of IP3R2 mRNA are normally high in healthy
nameof IP3R2 (used in theGeneSapiensmicroarray database but not present in theﬁgure).
Fig. 4. Hypothetical model for the dual role of Bcl-2 in apoptosis in Bcl-2-dependent cancer B-cells and its relevance for the apoptotic response to either BH4-domain-targeting tools or
BH3-mimetic tools. A. The scheme shows two different situations where the cancer B-cells depend on Bcl-2 for their survival at the ER (like SU-DHL-4 diffuse large B-cell lymphoma
(DLBCL) cells) or at the mitochondria (like OCI-LY-1 DLBCL cells). Cancer B-cells have a constitutive B-cell-receptor signaling, which may lead to chronic IP3 signaling. Thus, they may
depend on Bcl-2 binding to the IP3R to prevent excessive Ca2+ signaling. This is particularly relevant due to the upregulated IP3/IP3R2/Ca2+-signaling cascade such as in SU-DHL-4
cells, where the most sensitive isoform (IP3R2) is highly expressed. We propose that these cancer cells are “primed-to-death” at the level of the ER and thus require Bcl-2 at the ER as
an inhibitor of IP3R channels. Interestingly, these cells have previously been characterized to display a low level of BH3-only/Bax/Bak signaling. On the other hand, cancer B-cells (such
as OCI-LY-1) may be protected from excessive Ca2+ signaling by having an IP3R isoform that is less sensitive to IP3 (i.e. IP3R3). Such cells do not require Bcl-2 binding to the IP3R.
Interestingly, these OCI-LY-1 cancer cells have previously been identiﬁed as “primed-to-death” at the level of the mitochondria via an upregulated BH3-only/Bax/Bak cascade. They are
thereby addicted to anti-apoptotic Bcl-2 at the mitochondria to neutralize BH3-only proteins and prevent Bax/Bak activation. B. Cancer B-cells addicted to Bcl-2 at the ER (such as
SU-DHL-4 cells) will be particularly sensitive to tools that target the BH4 domain of Bcl-2 (TAT-IDPS), thereby disrupting IP3R/Bcl-2 complexes and resulting in pro-apoptotic Ca2+
signaling. In contrast, cancer cells addicted to Bcl-2 at the mitochondria (such as OCI-LY-1 cells) will be resistant to BH4-domain-targeting molecules, since these tools do not interfere
with the ability of Bcl-2 to scaffold Bim and thus do not trigger Bax/Bak activation. C. In contrast to BH4-domain-targeting tools, BH3-mimetic drugs that target the hydrophobic cleft
of Bcl-2 will cause the release of Bim from anti-apoptotic Bcl-2 in cancer cells addicted to Bcl-2 at the mitochondria, thereby resulting in Bax/Bak activation and MOMP. Cancer cells
addicted to Bcl-2 at the ER on the other hand will be relatively resistant to BH3-mimetic drugs, since these tools do not interfere with IP3R/Bcl-2-complex formation and thus do not
provoke pro-apoptotic Ca2+ signaling.
2248 H. Akl et al. / Biochimica et Biophysica Acta 1843 (2014) 2240–2252outcome of chemotherapeutic treatments of patients diagnosed with
different cancers. Our understanding of targeting Bcl-2 at the ER in
cancer cells is still in its infancy. However, the fact that peptide tools
that antagonize the BH4 domain of Bcl-2 at the level of the ER can kill
DLBCL cancer cell lines and primary CLL cells, shows that this might be
a promising and unprecedented anti-cancer therapy for at least a subset
of Bcl-2-dependent cancers.
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